The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...